CDK2 and neoplasm: Since upregulated expression of CDK2, CCNE, DNMT1 is associated with accelerated cell cycle progression and thus tumor growth [33, 40] these results suggest that the tumors might have started to develop a drug resistance after initially responding to the treatment with gemcitabine (Fig. 6a,c).